Mumbai-based global pharma major Lupin, signed a distribution agreement with Slovenia-based Medis for Lupin’s orphan drug NaMuscla® (mexiletine). Medis will commercialize NaMuscla® for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in Central and Eastern European countries, namely Croatia, Czech Republic, Hungary, Slovakia, and Slovenia in...
Medis, Axantia, Source Orphan Drugs from India’s Lupin
Mumbai-based global pharma major Lupin, signed a distribution agreement with Slovenia-based Medis for Lupin’s orphan drug NaMuscla® (mexiletine). Medis will commercialize NaMuscla® for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders in Central and Eastern European countries, namely Croatia, Czech Republic, Hungary, Slovakia, and Slovenia in...